Latest Lorcaserin Stories

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

2008-07-09 09:01:02

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis and other related conditions. The Phase 1b trial was a randomized, double-blind, placebo-controlled, multiple-ascending dose trial in 50...

Arena Pharmaceuticals Announces Results of Its Phase 1b Safety Study for Its Novel Anti-Obesity Compound

2004-11-30 09:00:10

SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity. APD356 is a selective agonist of 5-HT2C serotonin receptors, which are concentrated in the hypothalamus, an area of the brain believed to play an important role in regulating food intake and metabolism. The...